Acceleron Pharma (XLRN) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Reports In-Line Q4 EPS

Acceleron Pharma (XLRN) PT Raised to $46 at RBC Capital

February 28, 2018 7:44 AM EST

RBC Capital raised its price target on Acceleron Pharma (NASDAQ: XLRN) to $46.00 (from $44.00) while maintaining a Sector Perform rating.

... More

Acceleron Pharma (XLRN) PT Raised to $65 at Ladenburg Thalmann

February 28, 2018 6:45 AM EST

Ladenburg Thalmann raised its price target on Acceleron Pharma (NASDAQ: XLRN) to $65.00 (from $54.00) while maintaining a Buy rating.

Analyst Geoffrey Porges remains positive on the company noting Luspatercept is progressing and muscle programs offer upside over the LT.

... More

JPMorgan Upgrades Acceleron Pharma (XLRN) to Overweight

February 26, 2018 4:27 AM EST

JPMorgan upgraded Acceleron Pharma (NASDAQ: XLRN) from Neutral to Overweight with a price target of $52.00 (from $33.00).

Analyst Eric Joseph sees upside in the company's pivotal mid-year Luspatercept datasets. The analyst believes there are multiple levers for upside in the model due to... More